Moderna, Merck mRNA Cancer Vaccine Prevents Melanoma From Returning in Trial
The personalized vaccine and Keytruda cut the risk of melanoma returning or death by 49%, Merck and Moderna said.
- Moderna and Merck reported their personalised mRNA vaccine helped prevent melanoma from returning or spreading in a large trial involving more than 1,000 patients, combining the vaccine with Merck's Keytruda immunotherapy.
- Trial data showed adding the vaccine to Keytruda reduced the risk of cancer returning or death by 49 per cent, using synthetic mRNA coding for up to 34 neoantigens to target each patient's unique tumour mutations.
- The combination also reduced the risk of cancer spreading to distant parts of the body or death by 59 per cent, which Julie Gralow, Chief Medical Officer of the American Society of Clinical Oncology, called a "monumental leap forward."
- Ryan Sullivan, director of the Centre for Melanoma at Mass General Brigham Cancer Institute, described the findings as "a big deal for the field in general," as trials expand to include lung, bladder, and kidney cancers.
- The American Cancer Society estimates roughly 112,000 new cases of invasive melanoma in 2026, while Robert Vonderheide, president-elect of the American Association for Cancer Research, said, "We should be hearing results from multiple studies over the next few years, and there's every reason to hope now.
20 Articles
20 Articles
Never has ESMO, the Congress of the European Society of Medical Oncology, been so eagerly awaited this year.The meeting will take place in Madrid from 23 to 27 October, and it is expected that the Moderna and MSD pharmaceutical companies (Merck in the United States) will show concrete data from one of the most anticipated investigations: the trial of the first melanoma RNA vaccine.Last week the two companies launched an appetizer of their progre…
Hope for cancer patients as scientists report breakthrough in personalised cancer vaccines
Merck and Moderna said the vaccine helped prevent the return and spread of melanoma in a large trial involving more than 1,000 patients. The post Hope for cancer patients as scientists report breakthrough in personalised cancer vaccines appeared first on Premium Times Nigeria.
“A melanoma vaccine successfully surpasses a phase III clinical trial.” Thus stated, the advance made public by Merck and Moderna companies
Why Is MRNA Stock Up Today? Moderna Closes 177% Higher
A week ago, 14 out of 15 Wall Street analysts covering Moderna rated the stock either Hold or Sell. The average price target sat at $48.92. On August 19, the stock closed at $174.38. That is not a typo. Moderna (MRNA) gained 177% in a single session, on trading volume of 185.1 million shares, roughly 19 times its three-month average. The trigger: Moderna and Merck announced that their individualized mRNA cancer therapy, intismeran autogene, met …
Coverage Details
Bias Distribution
- 34% of the sources lean Left, 33% of the sources are Center, 33% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
